News - Page 201 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Nova Mentis Launches Autism Microbiome Study in the United States

Nova Mentis Launches Autism Microbiome Study in the United States

Post published:March 3, 2021
Post category:Press Release

Read more about the article Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial

Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial

Post published:March 2, 2021
Post category:Press Release

Read more about the article Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

Experiential Psilocybin-assisted Therapy Training Program, Approved by Health Canada, Gets Underway

Post published:March 2, 2021
Post category:Analysis News

Read more about the article OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development

OPTIMI HEALTH and NUMINUS WELLNESS to Conduct Psychedelic Lab Research and Development

Post published:March 2, 2021
Post category:Press Release

Red Light Holland Launches New Logo and Interactive Wisdom Truffle Companion Created by Internationally Renowned & Award-Winning Designer Karim Rashid

Post published:March 2, 2021
Post category:Press Release

Read more about the article PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization

Post published:March 2, 2021
Post category:Press Release

Read more about the article COMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021

COMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021

Post published:March 2, 2021
Post category:Press Release

Read more about the article PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease

Post published:March 2, 2021
Post category:Press Release

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Post published:March 2, 2021
Post category:Press Release

Read more about the article NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

Post published:March 2, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.